Eman Bahrani, MD
Dermatology · Nashville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 10 years
- Baylor College of Medicine, 2016
Offices
1 location · Vanderbilt University Medical Center · 3,510 clinicians in this group
Hospitals listed: Vanderbilt University Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bahrani’s office at (615) 322-3000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A152474 · Delinquent
Licence status: Delinquent · since 2017 · expires 2023-11-30 · Baylor College of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Tennessee 66159Medical Doctor · since 2022 · expires 2027-11-30Specialty on the licence: Dermatology; DermatopathologyLicensedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
3 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- Baylor College of Medicine · MDHouston, TX · 2016Medical school
Residency and fellowship
- Fellowship, DermatopathologyPalo Alto, CA · 2020–2021
- Residency, DermatologySan Francisco, CA · 2017–2020
- Internship, Internal MedicineCambridge, MA · 2016–2017
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Vanderbilt University Medical CenterNashville, TNAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Vanderbilt Health, which runs 4 hospitalsHome of Vanderbilt-Ingram Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Postoperative hemorrhage or hematoma rate: 3.28 (2.41 to 4.15) · 6,585 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.2 (0.85 to 1.54) · 15,700 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.591, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.703, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,175 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Vanderbilt University Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.28 (2.41 to 4.15) · 6,585 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.2 (0.85 to 1.54) · 15,700 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.591 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.703 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,175 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.56 to 1.87) · 4,737 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.13 (0.97 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.72 (117.43 to 174.02) · 459 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.6 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 223 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.2 · 632 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 466 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 557 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 7,242 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.14 to 0.46) · 17,585 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.05 to 0.37) · 18,947 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.16 (1.96 to 4.35) · 7,265 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.44 to 2.22) · 4,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.05 (6.38 to 11.73) · 4,115 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.74 (3.02 to 6.45) · 4,325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.48 to 2.84) · 1,745 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 156 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 1.072 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.406 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.337 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 400 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 1,055 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -18 · 288 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.6 · 752 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -10.7 · 504 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 668 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.2 to 6.4) · 1,413 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (9.9 to 13) · 1,413 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 162 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.9 (8.8 to 13.5) · 4,301 cases | No different | Jan 2022 – Dec 2024 |
What patients said (1,643 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$49,364
Medicare paid this office $49,364 for 412 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 128 | $11,094 | $67 |
| Short return visit (20+ min) | 147 | $9,546 | $44 |
| Pathology examination of tissue using a microscope, intermediate complexity | 189 | $7,848 | $28 |
| Destruction of precancer skin growth, 1 growth | 98 | $4,401 | $34 |
| Destruction of skin growth, 1-14 growths | 64 | $3,289 | $46 |
See all 13 services
| Return visit (30+ min) | 128 | $11,094 | $67 |
| Short return visit (20+ min) | 147 | $9,546 | $44 |
| Pathology examination of tissue using a microscope, intermediate complexity | 189 | $7,848 | $28 |
| Destruction of precancer skin growth, 1 growth | 98 | $4,401 | $34 |
| Destruction of skin growth, 1-14 growths | 64 | $3,289 | $46 |
| Biopsy of related skin growth, first growth | 119 | $3,060 | $19 |
| Biopsy of related skin growth, each additional growth | 61 | $1,696 | $15 |
| Special stained specimen slides to examine tissue, initial procedure | 41 | $1,215 | $26 |
| Special stained specimen slides to examine tissue, each additional procedure | 19 | $1,059 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 74 | $619 | $1 |
| Special stained specimen slides to identify organisms including interpretation and report | 12 | $288 | $18 |
| Punch biopsy, first skin growth | 11 | $287 | $24 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 21 | $284 | $13 |
Procedures Medicare counted
| Removal of skin lesions | 147 | More than 78% of doctors who do this |
| Skin biopsy | 154 | More than 81% of doctors who do this |
Procedures year by year
| Procedure | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | – | 90 | 428 | 424 |
| Biopsy of related skin growth, first growth | – | 24 | 123 | 159 |
| Destruction of precancer skin growth, 1 growth | – | 37 | 135 | 129 |
| Biopsy of related skin growth, each additional growth | – | – | 99 | 115 |
| Destruction of skin growth, 1-14 growths | – | 15 | 82 | 72 |
| Punch biopsy, first skin growth | – | – | 30 | 12 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
412 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 10% · Women 51% · Also on Medicaid 3% · Health risk score 1.35. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 69% · Chronic kidney disease 28% · Coronary heart disease 26% · Diabetes 24% · Depression 22% · Cancer 20% · Atrial fibrillation 18% · Heart failure 12% · COPD 8% · Stroke 6% · Dementia 5%.
The office billed $318,842, Medicare allowed $66,594 and paid $49,364; for 1,816 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 412 | 1,816 | 74 | 1.35 | $318,842 | $49,364 |
| 2023 | 242 | 1,374 | 72 | 1.83 | $254,688 | $40,161 |
| 2022 | 99 | 317 | 72 | 1.24 | $79,010 | $13,247 |
| 2021 | 23 | 70 | 71 | 1.81 | $31,260 | $5,607 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 116 | $11,536 | $68 |
| Short return visit (20+ min) | 121 | $7,567 | $44 |
| Destruction of precancer skin growth, 1 growth | 96 | $4,383 | $32 |
| Destruction of skin growth, 1-14 growths | 61 | $3,674 | $45 |
| Biopsy of related skin growth, first growth | 100 | $2,325 | $19 |
| New patient visit (45+ min) | 20 | $1,664 | $83 |
| Biopsy of related skin growth, each additional growth | 51 | $1,559 | $16 |
| New patient visit (30+ min) | 20 | $988 | $49 |
| Punch biopsy, first skin growth | 28 | $844 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 77 | $609 | $1 |
2022: 8 services
| Return visit (30+ min) | 26 | $3,021 | $92 |
| New patient visit (45+ min) | 28 | $3,011 | $108 |
| Destruction of precancer skin growth, 1 growth | 36 | $1,369 | $37 |
| Short return visit (20+ min) | 22 | $1,291 | $54 |
| New patient visit (30+ min) | 20 | $1,117 | $56 |
| Destruction of skin growth, 1-14 growths | 15 | $716 | $48 |
| Biopsy of related skin growth, first growth | 23 | $629 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $212 | $2 |
Medicaid work
$25,933 in 2022
Medicaid paid $25,933 for 242 billed services this clinician did in 2022, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 81 | $25,801 |
| Short return visit (20+ min) | 88 | $132 |
| Service | 73 | $0 |
| 2022 | 242 | 3 | 32 | $25,933 |
| 2021 | 338 | 3 | 40 | $40,224 |
| 2019 | 45 | 1 | 23 | $0 |
See the largest Medicaid services in earlier years
2021
| Clinic visit/encounter, all-inclusive | 127 | $39,939 |
| Short return visit (20+ min) | 105 | $284 |
| Service | 106 | $0 |
2019
| Short return visit (20+ min) | 45 | $0 |
Drugs they prescribed that Part D paid
$675,393
Pharmacies billed $675,393 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 503) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
409 generic and 94 brand-name prescriptions · $675,393 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 49 | $297,629 | $6,074 |
| Opzelura | 15 | $63,252 | $4,217 |
| Fluorouracil | 27 | $1,924 | $71 |
| Ketoconazole | 46 | $851 | $19 |
| Fluocinolone Acetonide | 18 | $675 | $37 |
See all 15 drugs
| Dupixent | 49 | $297,629 | $6,074 |
| Opzelura | 15 | $63,252 | $4,217 |
| Fluorouracil | 27 | $1,924 | $71 |
| Ketoconazole | 46 | $851 | $19 |
| Fluocinolone Acetonide | 18 | $675 | $37 |
| Imiquimod | 14 | $626 | $45 |
| Ciclopirox | 21 | $479 | $23 |
| Hydrocortisone | 29 | $460 | $16 |
| Metronidazole | 12 | $435 | $36 |
| Clindamycin Phosphate | 15 | $430 | $29 |
| Minoxidil | 25 | $295 | $12 |
| Triamcinolone Acetonide | 27 | $292 | $11 |
| Mupirocin | 26 | $199 | $8 |
| Gabapentin | 14 | $143 | $10 |
| Hydroxychloroquine Sulfate | 11 | $118 | $11 |
Year by year
| 2024 | 503 | 153 | 0% (0) | 19% | $675,393 |
| 2023 | 423 | 139 | None | 22% | $650,424 |
| 2022 | 254 | 96 | 0% (0) | 7% | $72,870 |
| 2021 | 77 | 30 | 0% (0) | None | $2,956 |
| 2017 | 54 | 30 | None | None | $2,094 |
| 2016 | 34 | 22 | None | None | $560 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Dupixent | 54 | $322,051 | $5,964 |
| Opzelura | 14 | $61,343 | $4,382 |
| Clobetasol Propionate | 19 | $1,379 | $73 |
| Ketoconazole | 49 | $1,140 | $23 |
| Fluorouracil | 12 | $1,008 | $84 |
| Metronidazole | 14 | $931 | $66 |
| Clindamycin Phosphate | 14 | $620 | $44 |
| Triamcinolone Acetonide | 40 | $448 | $11 |
| Hydrocortisone | 38 | $322 | $8 |
| Hydroxychloroquine Sulfate | 12 | $182 | $15 |
| Prednisone | 28 | $175 | $6 |
| Mupirocin | 19 | $166 | $9 |
| Spironolactone | 14 | $114 | $8 |
| Gabapentin | 11 | $91 | $8 |
2022: 6 drugs
| Fluorouracil | 14 | $1,853 | $132 |
| Fluocinonide | 19 | $1,722 | $91 |
| Triamcinolone Acetonide | 51 | $1,124 | $22 |
| Clobetasol Propionate | 11 | $628 | $57 |
| Ketoconazole | 23 | $512 | $22 |
| Hydrocortisone | 12 | $126 | $11 |
2021: 1 drug
| Triamcinolone Acetonide | 20 | $446 | $22 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1073963997
- Licence
- CA A152474, TN 66159California A152474: Delinquent · expires 2023-11-30Tennessee 66159: Licensed
- Trained
- Baylor College of Medicine, 2016 · 10 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
- Mailing address
- 3841 Green Hills Village Dr, Nashville, TN, 37215
- NPI first listed
- 2016-06-21
- NPI last updated
- 2025-12-15
- NPI record certified
- 2025-12-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 330 Mount Auburn St, Cambridge, MA, 02138 · 995 Potrero Ave Bldg 90, San Francisco, CA, 94110
This office lists an electronic records connection.